“As a society, we’re behind the curve in tackling the Alzheimer’s pandemic. This is especially important since the number of Alzheimer’s patients in Japan is expected to rise to 13 million people by 2025. And insurance companies like Dai-ichi and SOMPO are helping the world’s largest aging population. The Japanese government has made it a national focus to reduce the number of people with dementia by 6% among people in their 70s by 2025. With each Neurotrack partnership, Dai-ichi and SOMPO are expecting to give millions of people in Japan access to tools for assessing and managing their cognitive health. “We believe in the power of Neurotrack’s products which is why we are a customer and now an investor.” “We are excited about the partnership between Neurotrack and Dai-ichi Life, and our joint continued dedication to lowering the growth rate of dementia in Japan,” added Yasumasa Iwai - the Executive Officer in Charge of Insurtech at Dai-ichi Life.
#Neurotracker demo plus
Plus Neurotrack and SOMPO are now working on deepening and extending their partnership. With each Neurotrack partnership, Dai-ichi and SOMPO are expecting to give millions of people in Japan access to tools for assessing and managing their cognitive health. In the first part of 2019, SOMPO conducted a 16-week pilot with Neurotrack where over 550 of SOMPO’s employees took Neurotrack’s test and followed along with the Memory Health Program for four months. Neurotrack partnered with Dai-ichi Life last year - which is the second largest life insurance company in Japan for making its products available to customers as part of its new dementia insurance product.
And now they’re also investing in our company, so these companies have two ways of doing well by doing good.” “These partnerships are innovative models that we hope to replicate in other markets, enabling traditional insurance companies to create new markets while helping to address the Alzheimer’s crisis. In Japan, for example, traditional insurance companies are developing novel solutions that incorporate Neurotrack’s products to advance better memory health among its population,” said Neurotrack co-founder and CEO Elli Kaplan in a statement. “As the global crisis around Alzheimer’s continues to grow, the private sector is joining government and nonprofits to address the problem in their markets. And Neurotrack found a way to bring cognitive health tools to millions around the world. There are more than an estimated 50 million people around the world living with Alzheimer’s today and more than 130 million expected by 2050. Neurotrack’s Memory Health Program has been essential in the fight against Alzheimer’s.
0 kommentar(er)
